CAS 1256580-46-7

Alectinib

Descripción:

Alectinib es un fármaco de molécula pequeña utilizado principalmente en el tratamiento del cáncer de pulmón de células no pequeñas (NSCLC) que es positivo para reordenamientos del gen de la quinasa del linfoma anaplásico (ALK). Funciona como un inhibidor selectivo de ALK, interrumpiendo las vías de señalización que promueven el crecimiento y la supervivencia del tumor. Alectinib se caracteriza por su alta potencia y especificidad para ALK, lo que ayuda a minimizar los efectos fuera del objetivo y mejora su eficacia terapéutica. El compuesto se administra típicamente por vía oral y tiene un perfil farmacocinético favorable, que incluye buena absorción y una larga vida media, lo que permite una dosificación una o dos veces al día. Su estructura química incluye un núcleo bicíclico, lo que contribuye a su capacidad para penetrar la barrera hematoencefálica, haciéndolo efectivo contra las metástasis cerebrales asociadas con NSCLC positivo para ALK. Los efectos secundarios comunes pueden incluir fatiga, estreñimiento y elevaciones de enzimas hepáticas, lo que requiere monitoreo durante el tratamiento. En general, Alectinib representa un avance significativo en la terapia dirigida contra el cáncer, ofreciendo mejores resultados para los pacientes con perfiles genéticos específicos.

Fórmula: C₃₀H₃₄N₄O₂

InChI: InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3

Clave InChI: InChIKey=KDGFLJKFZUIJMX-UHFFFAOYSA-N

SMILES: O=C1C2=C(C(C)(C)C=3C1=CC(CC)=C(C3)N4CCC(CC4)N5CCOCC5)NC=6C2=CC=C(C#N)C6

Sinónimos:

• 5H-Benzo[b]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-
• 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
• Af 802
• Alecensa free base
• Ch 5424802
• Ch 542480210
• Rg 7853
• Rg7853
• Alectinib
• Alectinib (CH5424802)
• AF-802,RG-7853
• CH5424802
• CH5424802-alectinib
• 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile Alectinib (CH5424802)

9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile

CAS: 1256580-46-7

Fórmula: C₃₀H₃₄N₄O₂

Pureza: 98%

Forma y color: Solid

Peso molecular: 482.6166

Ref: IN-DA000O9H

Alectinib

CAS: 1256580-46-7

Fórmula: C₃₀H₃₄N₄O₂

Forma y color: Off-White Solid

Peso molecular: 482.63

Ref: 4Z-A-239001

Alectinib

CAS: 1256580-46-7

Alectinib

Pureza: ≥98%

Peso molecular: 482.62g/mol

Ref: 54-BUP14479

Alectinib-d8

CAS: 1256580-46-7

Fórmula: C₃₀H₂₆D₈N₄O₂

Peso molecular: 490.68

Ref: 4Z-A-239006

Alectinib-d5

CAS: 1256580-46-7

Fórmula: C₃₀H₂₉D₅N₄O₂

Peso molecular: 487.66

Ref: 4Z-A-239005

Alectinib

CAS: 1256580-46-7

Alectinib (RG-7853) is an ALK inhibitor that is selective, orally active, and ATP-competitive. Alectinib has antitumor activity. Cost-effective and quality-assured.

Fórmula: C₃₀H₃₄N₄O₂

Pureza: 98% - 99.38%

Forma y color: Solid

Peso molecular: 482.62

Ref: TM-T1936

Alectinib

CAS: 1256580-46-7

Alectinib

Pureza: 98%

Peso molecular: 482.62g/mol

Ref: 54-BISN0151

CH5424802

Producto controlado

CAS: 1256580-46-7

Applications CH5424802 is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth. CH5424802 have been clinically evaluated for the treatment of patients with ALK-driven tumors. Potent ALK inhibitor
References Sakamoto, H., et al.: Cancer Cell., 19, 679 (2011); Kinoshita, K., et al.: Bio-org. Medn., 20, 1271 (2012);

Fórmula: C₃₀H₃₄N₄O₂

Forma y color: Neat

Peso molecular: 482.62

Ref: TR-C183360

Alectinib

CAS: 1256580-46-7

Alectinib is a drug that inhibits the activity of tyrosine kinases, including ALK, ROS1, and MET. It binds to ATP-binding sites in the active site of these enzymes and prevents them from transferring phosphate groups onto their substrates. Alectinib also inhibits the activity of polymerase chain reaction (PCR) in vitro by binding to DNA. This drug has been shown to inhibit the growth of lymphoma cells in mice by inhibiting protein synthesis and inducing apoptosis. Alectinib also acts as a p-glycoprotein (Pgp) inhibitor, which may be due to its ability to inhibit an alkaline phosphatase.

Fórmula: C₃₀H₃₄N₄O₂

Pureza: Min. 98 Area-%

Forma y color: White Powder

Peso molecular: 482.62 g/mol

Ref: 3D-FA75280

CH5424802-d8

Producto controlado

CAS: 1256580-46-7

Applications CH5424802-d8 is the labelled form of CH5424802 (C183360). CH5424802 is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth. CH5424802 have been clinically evaluated for the treatment of patients with ALK-driven tumors.
References Sakamoto, H., et al.: Cancer Cell., 19, 679 (2011); Kinoshita, K., et al.: Bio-org. Medn., 20, 1271 (2012)

Fórmula: C₃₀H₂₆D₈N₄O₂

Forma y color: Neat

Peso molecular: 490.67

Ref: TR-C183362